Skip to main content
$75.00 $0.79 (1.1%)

04:00 PM EDT on 06/11/21

Denali Therapeutics Inc (NASDAQ:DNLI)

CAPS Rating: 3 out of 5

Current Price $75.00 Mkt Cap $9.1B
Open $74.25 P/E Ratio 147.24
Prev. Close $75.00 Div. (Yield) $0.00 (0.0%)
Daily Range $73.35 - $75.29 Volume 481,444
52-Wk Range $22.36 - $93.94 Avg. Daily Vol. 527,314

Caps

How do you think NASDAQ:DNLI will perform against the market?

Add Stock to CAPS Watchlist

All Players

11 Outperform
2 Underperform
 

All-Star Players

3 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:DNLI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:DNLI VS S&P 500 (SPY)

NASDAQ:DNLI Summary

Fools bullish on NASDAQ:DNLI are also bullish on:

Fools bearish on NASDAQ:DNLI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about DNLI.

Recs

0
Member Avatar mrbill6 (65.22) Submitted: 11/2/2020 2:22:02 PM : Outperform Start Price: $43.19 NASDAQ:DNLI Score: +44.63

Awaiting scientific testing results

Recs

0
Member Avatar mdriver78 (75.23) Submitted: 1/22/2020 11:03:08 AM : Outperform Start Price: $20.82 NASDAQ:DNLI Score: +221.58

Hope just got a little brighter for those who have Parkinson’s disease. Researchers indicate a signaling protein known as leucine-rich repeat kinase (LRRK2) is a key factor influencing the development of Parkinson’s disease.

High levels of LRRK2 activation are associated with malfunction of lysosomes, the “garbage collectors” in our brain cells. Some people have an overactive variant of the gene for this molecule.
And they also have an increased risk for developing this neurodegenerative disease.

DNLI) is making great progress in attacking this particular target as a way to treat Parkinson’s. The company has two different LRRK2-blocking drugs in clinical trials and recently updated investors on its progress.

One of the company’s therapies, DNL201, showed huge potential in patients by reducing biomarkers for LRRK2 by over 50% while showing no serious safety issues.

Denali’s second Parkinson’s drug, DNL151, showed early results in over 150 patients of a similar makeup — greater than 50% change — and dose-dependent reductions in lysosomal biomarkers as measured via urinalysis.

The company plans to move both drugs into Phase 2/3 clinical trials by the middle of 2020.

The market loved this news when it was released last week, driving DNLI shares up by some 30% in a single trading session.
But I suspect there’s much more to come beyond our current 41% gain in this brain health biotech. The company expects data to read out from its ALS trials by mid-2020, and its Alzheimer’s clinical trial is now fully enrolled.

Positive data from either of these programs would be a huge mover for DNLI shares, and the company has the potential to be worth thousands of percent more over time as it executes on its clinical pipeline.

What I like about Denali’s Alzheimer’s program is its unique approach to dealing with the disease.

We’ve seen huge high-profile drug trial failures in the Alzheimer’s space. Biogen Inc. recently tried to salvage a program that was discontinued in Phase 3 with an FDA submission for high-dose patients.

But high doses of Biogen’s drugs also meant high side effects.
Biogen’s drug, as well as many others, is based on what was the mainstream theory of this disease and repeated failures strongly suggested the theory was wrong.

Denali’s approach, however, is to attack inflammatory pathways in brain cells that lead to cell death. This concept may prove to have far more value, and if the company demonstrates this via clinical data, its own market value will rise.

Leaderboard

Find the members with the highest scoring picks in DNLI.

Score Leader

Biotoday

Biotoday (68.61) Score: +392.57

Collaborations with Takeda, Sanofi, and AbbVie.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Biotoday 68.61 7/26/2018 7/9/2020 Outperform 1Y $13.84 +442.10% +49.53% +392.57 0 Comment
jeepdrew222 80.57 12/22/2017 Outperform 5Y $16.20 +362.96% +58.82% +304.14 0 Comment
BOBBYLDc 65.41 6/7/2018 Outperform 5Y $18.76 +299.79% +53.12% +246.67 0 Comment
mdriver78 75.23 2/27/2020 Outperform 5Y $20.82 +260.23% +38.65% +221.58 1 Comment
TMFSaintCroix 99.69 4/11/2019 4/6/2020 Outperform 5Y $28.22 +165.77% +46.91% +118.86 0 Comment
mrbill6 65.22 11/2/2020 5/23/2021 Outperform 3W $43.19 +73.65% +29.02% +44.63 1 Comment
kkconway 99.28 4/29/2021 Outperform 5Y $60.65 +23.66% +1.54% +22.12 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Paco57 66.22 11/9/2020 Outperform 5Y $54.55 +37.49% +16.58% +20.91 0 Comment
TMFjimhalley 59.20 11/9/2020 Outperform 5Y $54.55 +37.49% +16.58% +20.91 0 Comment
naylorj 76.55 11/11/2020 Outperform 1Y $59.80 +25.42% +19.05% +6.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DNLI.